CALL - SPRINTER OPEN END - NOVO-NORDISK B | Market Closed - Borsa Italiana 16:04:59 2024-06-28 EDT | ||
| 6.06 EUR | -.--% |
|
| 1 month | +20.48% | ||
| 3 months | +29.49% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 6.06 | -1.62% |
| 24-06-27 | 6.16 | +0.33% |
| 24-06-26 | 6.14 | -4.21% |
| 24-06-25 | 6.41 | +8.09% |
| 24-06-24 | 5.93 | +0.34% |
Real-time Borsa Italiana
Last update June 28, 2024 at 04:04 pm
More quotesStatic data
| Product type | Warrant Knock-Out senza Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| F39773 | |
| ISIN | DE000VM0PZV9 |
| Date issued | 2023-09-15 |
| Strike | 552.2 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.15 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.64 € |
|---|---|
| Lowest since issue | 1.283 € |
| Spread | 0.14 € |
| Spread % | 2.29% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006
DKK
Average target price
949.7
DKK
Spread / Average Target
-5.56%
- Stock Market
- Certificates
- F39773 Certificat
